Kanvas Biosciences
Develops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapy
$48MSeries A
Role not disclosedG
Gaingels
Activity from announced rounds
Activity in this selectionSeries A
Gaingels co-invests alongside venture leads in companies committed to diverse and inclusive teams, spanning seed through growth and pre-IPO rounds across technology, healthcare and consumer markets.
Its investor community includes LGBTQ+ people and allies, extending representation within the ownership of venture-backed companies. Portfolio companies work with its Gaingels Letter commitments and Venture Inclusion programme on building more inclusive organisations.
A board access programme provides free recruitment advice for diverse board members and observers. This gives founders a practical governance resource alongside a co-investment partner for a round led by another venture firm.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $297M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionLatus Bio, Inc.
Engineers scalable AAV gene therapies for CNS and rare diseases including Huntington's disease and CLN2
$97MSeries A
Role not disclosedRapidFort
Provides continuous vulnerability remediation for software supply chain security
$42MSeries A
Role not disclosedNeurophos
Develops photonic AI inference chips for data centers
$110MSeries A
Role not disclosed